

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

## PEER-REVIEW REPORT

Name of journal: World Journal of Clinical Cases

Manuscript NO: 69882

**Title:** Iguratimod in treatment of primary Sjögren's syndrome concomitant with autoimmune hemolytic anemia: A case report

Peer-Review Report: Unsolicited manuscript; Externally peer reviewed

Peer-review model: Single blind

Reviewer's code: 05386374

**Position:** Peer Reviewer

Academic degree: MD

Professional title: Doctor

Reviewer's Country/Territory: Iran

Author's Country/Territory: China

Manuscript submission date: 2021-07-29

Reviewer chosen by: AI Technique

Reviewer accepted review: 2021-08-12 20:28

Reviewer performed review: 2021-08-12 22:42

Review time: 2 Hours

Scientific quality	[ ] Grade A: Excellent [ ] Grade B: Very good [Y] Grade C: Good [ ] Grade D: Fair [ ] Grade E: Do not publish
Language quality	<ul> <li>[ ] Grade A: Priority publishing [Y] Grade B: Minor language polishing</li> <li>[ ] Grade C: A great deal of language polishing [ ] Grade D: Rejection</li> </ul>
Conclusion	<ul> <li>[ ] Accept (High priority) [ ] Accept (General priority)</li> <li>[ ] Minor revision [ Y] Major revision [ ] Rejection</li> </ul>
Re-review	[Y]Yes []No



Baishideng **Publishing** 

7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA **Telephone:** +1-925-399-1568 **E-mail:** bpgoffice@wjgnet.com https://www.wjgnet.com

Peer-reviewer	Peer-Review: [Y] Anonymous [] Onymous
statements	Conflicts-of-Interest: [ ] Yes [Y] No

## SPECIFIC COMMENTS TO AUTHORS

- The term "misdiagnose" (page 8, line 132), which refers to an incorrect diagnosis of an illness or disease, might carry an unnecessary exaggeration. For all we know, autoimmune hemolytic anemia was diagnosed perfectly, and the concomitant Sjögren's syndrome was neglected. Therefore, it might be better to address the Sjögren's as a "missed" diagnosis instead. - A paragraph should be included in the discussion about the Iguratimod mechanisms of action that were possibly effective in treating this patient (the reason why this agent could be considered as a treatment option for these patients). - What were the limitations of this case report? - What are the authors' clinical recommendations (diagnosis of similar patients, treatment steps, duration of follow-up, etc.), and suggestions for further research in the field? - The manuscript is well-written; however, I recommend the authors to proofread the manuscript to correct some minor mistakes.